Anuradha Pandey - Mangalam Drugs Company Officer
| MANGALAM | 121.24 0.89 0.73% |
Executive
Anuradha Pandey is Company Officer of Mangalam Drugs And
| Age | 31 |
| Address | Rupam Building, Mumbai, India, 400001 |
| Phone | 91 22 6261 6200 |
| Web | https://www.mangalamdrugs.com |
Mangalam Drugs Management Efficiency
The current year's Intangible Assets is expected to grow to about 299.4 M, whereas Total Assets are forecasted to decline to about 2.1 B. Mangalam Drugs' management efficiency ratios could be used to measure how well Mangalam Drugs manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Vivek Vadwana | UTI Asset Management | N/A | |
| Jignesh Sangani | The Investment Trust | 57 | |
| Gayatri Karandikar | BF Investment Limited | N/A | |
| Vivek K | UTI Asset Management | N/A | |
| Supriya Sapre | HDFC Asset Management | N/A | |
| Alok Sheopurkar | HDFC Asset Management | 56 | |
| Suresh Babu | HDFC Asset Management | 57 | |
| Shyamkumar Gupta | UTI Asset Management | N/A | |
| Sylvia Furtado | HDFC Asset Management | 54 | |
| Naozad Sirwalla | HDFC Asset Management | 52 | |
| Smriti Mehra | Network18 Media Investments | N/A | |
| Sakthivel | Network18 Media Investments | 65 | |
| Rajneesh Singh | Network18 Media Investments | N/A | |
| Sonali Chandak | HDFC Asset Management | N/A | |
| Amandeep Chopra | UTI Asset Management | N/A | |
| Sudip Roy | Network18 Media Investments | N/A | |
| Surojit Saha | UTI Asset Management | N/A | |
| Shobhit Mehrotra | HDFC Asset Management | 58 | |
| Pranav Shah | The Investment Trust | ||
| CS CA | Network18 Media Investments | 52 | |
| Shridhar Mishra | Network18 Media Investments | N/A | |
Management Performance
| Return On Equity | -0.0631 | ||||
| Return On Asset | 0.005 |
Mangalam Drugs And Leadership Team
Elected by the shareholders, the Mangalam Drugs' board of directors comprises two types of representatives: Mangalam Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mangalam. The board's role is to monitor Mangalam Drugs' management team and ensure that shareholders' interests are well served. Mangalam Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mangalam Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brijmohan Dhoot, WholeTime Director | ||
| Kamal Vashi, President | ||
| Krishnapriya Nawal, Chief Officer | ||
| Govardhan Dhoot, Chairman MD | ||
| Anuradha Pandey, Company Officer | ||
| Jayant Barde, Company Officer | ||
| Ajay Samant, Chief Officer | ||
| Yaduraj Dhoot, Head Purchase |
Mangalam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mangalam Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0631 | ||||
| Return On Asset | 0.005 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 2.6 B | ||||
| Shares Outstanding | 15.83 M | ||||
| Shares Owned By Insiders | 54.58 % | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 0.54 X | ||||
| Revenue | 3.67 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Mangalam Stock
Mangalam Drugs financial ratios help investors to determine whether Mangalam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mangalam with respect to the benefits of owning Mangalam Drugs security.